Immunogenicity, Safety and Reactogenicity of Ad26.RSV.preF/RSV Pref Protein Vaccine in Adults Aged 60 to 75 Years: A Comparison of Phase 2b and Phase 3 Clinical Trial Material
HUMAN VACCINES & IMMUNOTHERAPEUTICS（2024）
关键词
Respiratory syncytial virus,RSV,vaccine,Ad26, immunogenicity, Ad26.RSV.preF, RSV preF protein
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要